ZARXIO Q Code: Q5101
Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
Q4 2026 Medicare Payment Limit for Q5101, effective October 1, 2026: $0.338 per HCPCS billing unit, down 4.2% from $0.353. From CMS's final file.
Drug & Product Overview
About ZARXIO
Zarxio is a medication aligned to the HCPCS Q Code: Q5101 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology Colony Stimulating Factor, it is administered via the intravenous or subcutaneous routes and manufactured by Sandoz.
According to CMS Drug Use Information: Filgrastim is a man-made version of a certain natural substance made by your body. It is used to help your body make more white blood cells. White blood cells are important to help you fight off infections. Filgrastim is given to people whose ability to make white blood cells is reduced (for instance, due to chemotherapy, chronic neutropenia, or exposure to large amounts of radiation). It is also used in certain treatment procedures (such as bone marrow/stem cell transplant). This monograph is about the following filgrastim products: filgrastim, filgrastim-aafi, filgrastim-ayow, filgrastim-laha, filgrastim-sndz, filgrastim-txid, and tbo-filgrastim.
Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.
NDC Code Information
Based on publicly available CMS files. The list of NDCs below is not exhaustive.
| NDC Code | Drug | Manufacturer | Billing Units / Pkg | Package Size |
|---|---|---|---|---|
| 61314-0318-01 | Zarxio | Sandoz Inc. | 300 | 300 MCG / 0.5 ML |
| 61314-0318-10 | Zarxio | Sandoz Inc. | 3000 | 300 MCG / 0.5 ML |
| 61314-0326-01 | Zarxio | Sandoz Inc. | 480 | 480 MCG / 0.8 ML |
| 61314-0326-10 | Zarxio | Sandoz Inc. | 4800 | 480 MCG / 0.8 ML |
ZARXIO Pricing & Reimbursement
National median reimbursement across major commercial payers.
Create an account on PayerPrice for more information →Historical Graphing and Billing Calculator
Log in to calculate billing and reimbursement with live ASP, WAC & AWP pricing.
Login to use the calculator →Filgrastim Biosimilar Information:
ZARXIO Approval Date: March 6, 2015
| Product Name | HCPCS Code | Active Ingredient | BLA Type |
|---|---|---|---|
| Neupogen | J1442 | Filgrastim | 351(a) Originator Product |
| Zarxio | Q5101 | Filgrastim | 351(k) Biosimilar |
| Nivestym | Q5110 | Filgrastim | 351(k) Biosimilar |
| Releuko | Q5125 | Filgrastim | 351(k) Biosimilar |
| Nypozi | Q5148 | Filgrastim | 351(k) Biosimilar |
| Filkri | Q5172 | Filgrastim | 351(k) Biosimilar |
ZARXIO Claims Performance
Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.
Explore Q5101 claims analytics on FocalPoint →
ZARXIO CPT Administration Codes
The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.
| CPT Code | Description |
|---|---|
| 96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular |
CMS has identified Zarxio (Q5101) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →
ZARXIO Medically Unlikely Edits (MUE)
The most billing units of Q5101 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mcg.
MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →
ZARXIO Clinical Information
Indications and drug classification.
This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.
Login for BuyandBill.com Analytics
Unlock deeper insights with BuyandBill’s Comparative Report!
- Compare ASP, WAC, and AWP across drugs.
- Visualize Drug Price Movement Over Time
- Tailor reports to drug class, manufacturer, or HCPCS Code.
- Compare Biosimilar and 505(b)(2) products.
Frequently Asked Questions
Is there an available Zarxio billing and coding guide?
Are there any available Zarxio patient assistance programs?
Where can I find Zarxio prescribing information?
Where can I find Zarxio side effect information?
Does billing ZARXIO require JZ/JW wastage modifiers?
About BuyandBill.com:
The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.
Related Drug Codes
Explore billing, coding, and pricing for drugs related to ZARXIO.